Filing Flows › Bio-Rad Laboratories (BIO) › Q4 2025
Bio-Rad Laboratories (BIO) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Feb 13, 2026
Bio-Rad Laboratories (BIO) reported revenue of $693M for the fourth quarter 2025 (Q4 2025), +4% from a year earlier and +6% from the quarter before. Operating margin was -17.2%, net earnings $720M (103.9% of revenue).
Bio-Rad Laboratories, Q4 2025: revenue $693M (+4% year over year), operating margin -17.2%, net earnings $720M, operating cash flow $165M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $693M | +6% | +4% |
| Operating profit | −$119M | -282% | — |
| Net earnings | $720M | — | — |
| Operating cash flow | $165M | +36% | +33% |
| Free cash flow | $119M | +34% | +46% |
What changed
Revenue was $693.2M in Q4 2025, up 4% year over year and up 6% from the previous quarter. Clinical Diagnostics was the largest line at 61% of revenue.
Gross margin was 49.8%, down 1.4 points from a year earlier. Operating costs exceeded revenue by $118.9M, an operating margin of -17.2%. Operating expenses grew 64% against revenue growth of 4%. Net earnings were $720.0M. The effective tax rate was 22.5%. Non-operating items added $1,048.1M, 113% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was $164.9M (up 33% year over year), 23% of net earnings. Non-cash charges added back $15.9M of share-based compensation. Working capital and other items used $571.0M. Capital expenditures of $45.8M left free cash flow of $119.1M.
Questions
What was Bio-Rad Laboratories' revenue in the fourth quarter 2025?
Bio-Rad Laboratories (BIO) reported revenue of $693M for the fourth quarter 2025 (Q4 2025), +4% from a year earlier and +6% from the quarter before.
Was Bio-Rad Laboratories profitable in the fourth quarter 2025?
Operating loss was $119M (-17.2% of revenue) and net earnings $720M.